A total of 73 patients diagnosed with LM were treated with osimertinib, including 64 patients evaluable for the LM efficacy set—T790M negative (n = 62) and T790M positive (n = 2). The median OS in the ...

Northern TK Venture Pte Ltd. (NTK), an indirect subsidiary of IHH Healthcare Berhad, has raised its damages claim against Daiichi Sankyo Company, Limited from $179.7m (¥20b / RM 634m) to $1.8b ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 20 abstracts in multiple cancers at the 2025 American Society of Clinical Oncology ...

bWHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China Pandemic ...

(Image/Reuters) Northern TK Venture (NTK), a Singapore-based indirect arm of Malaysia’s IHH Healthcare, has raised its damages claims against Japanese pharma firm Daiichi Sankyo Company by ...

IHH Healthcare, supported by Mitsui, has increased its compensation claim against Daiichi Sankyo to $1.3 billion in the Tokyo District Court, related to the Fortis Healthcare acquisition.

IHH Healthcare, Asia’s largest healthcare operator, on Tuesday said it is now seeking a revised ¥200 billion (approximately Rs 11,800 crore or $1.38 billion) in damages from Japan’s Daiichi Sankyo for ...

Global Antibody Drug Conjugates Market Report 2025-2035, Featuring F. Hoffmann La Roche, Daiichi Sankyo, Seagen, Gilead Sciences, Takeda, Pfizer, Astellas, AstraZeneca, ADC Therapeutics and Immunogen ...

Merck MRK and Japan’s Daiichi Sankyo announced the dosing of the first patient in the phase III IDeate-Esophageal01 study evaluating their B7-H3 directed DXd antibody-drug conjugate (ADC ...